Healthcare Sector Screener
Healthcare is a defensive sector with a diverse risk profile. Large pharma offers stability and dividends; biotech carries binary event risk (FDA approvals). Political risk (drug pricing legislation) and patent cliffs are key sector-specific headwinds.
Screen Healthcare stocks by trend, momentum, and fundamentals
Filter by RSI, revenue growth, margins, ELO ranking, and more.
Key Macro Drivers
Top Valuation Metrics
About the Healthcare Sector
Healthcare is one of the most complex and diverse sectors in the market, encompassing pharmaceutical manufacturers, biotechnology companies, medical device makers, managed care organizations, and healthcare facilities.
Large-cap pharmaceutical companies (Big Pharma) are characterized by stable revenue from established drug franchises, significant R&D pipelines, and meaningful dividend yields. Their key risks are patent expirations ("patent cliffs") where generic competition sharply cuts revenue from blockbuster drugs, and drug pricing legislation from Congress or CMS.
Biotech is a different animal entirely. Small and mid-cap biotechs often have no revenue — their value is the probability-weighted expected value of pipeline assets. Binary events (FDA approval/rejection, Phase 2/3 trial readouts) can cause 50–100% moves in a single session. Monitoring catalyst calendars (PDUFA dates, trial data readout windows) is essential for biotech traders.
Medical device companies are more stable than biotech — they sell recurring consumables and capital equipment with established reimbursement. Health insurers (managed care) track medical loss ratios and premium growth. Each sub-industry in healthcare has distinct drivers.
Related Sectors
Frequently Asked Questions
- What is a PDUFA date and why does it matter?
- A PDUFA date is the FDA's deadline to act on a drug application. It's the binary event that defines a biotech stock's near-term trajectory — approval can double the stock; rejection can cut it in half. PDUFA dates are published months in advance and are key catalyst calendar events.
- How does healthcare perform in recessions?
- Healthcare is one of the most defensive sectors — people need medical care regardless of economic conditions. Large-cap pharma and medical devices tend to hold value well during recessions. Biotech is the exception — risk-off environments hit speculative names hard due to funding constraints.
- What metrics matter for evaluating pharma vs. biotech?
- For pharma: revenue diversification (% from top drugs), pipeline strength, patent expiry schedule, and FCF generation. For biotech: probability-adjusted pipeline value, cash runway (months of operating expenses covered by cash), and management's track record of regulatory success.
- How does drug pricing legislation affect healthcare stocks?
- Congressional drug pricing legislation (like Medicare negotiation provisions) directly reduces revenue for the pharma companies whose drugs are targeted. Watch for annual Medicare drug price negotiation announcements, which are published and create predictable windows of sector volatility.
Data is provided for informational purposes only and does not constitute investment advice. Sector analysis reflects general characteristics and does not account for individual stock performance. Past performance is not indicative of future results.